Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2003 Jun 7;326(7401):1235.
doi: 10.1136/bmj.326.7401.1235.

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

Nicola J Cooper  1 , Alexander J Sutton, Keith R Abrams, Allan Wailoo, David Turner, Karl G Nicholson
Affiliations
Meta-Analysis

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

Nicola J Cooper et al. BMJ. .

Abstract

Objective: To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and prevention of influenza A and B.

Design: Systematic review and meta-analyses of randomised controlled trials.

Data sources: Published studies were retrieved from electronic bibliographic databases; supplementary data were obtained from the manufacturers.

Selection of studies: Randomised controlled, double blind trials that were published in English, had data available before 31 December 2001, evaluated treatment or prevention of naturally occurring influenza with zanamivir or oseltamivir (if given using the formulation and dosage licensed for clinical use), and reported at least one end point of relevance.

Review methods: The main outcome measures were the median time to the alleviation of symptoms (for treatment trials) and number of flu episodes avoided (for prevention trials). Three population groups were defined: children aged 12 years and under; otherwise healthy individuals aged 12 to 65 years; and "high risk" individuals (those with certain chronic medical conditions or aged 65 years and older).

Results: Seventeen treatment trials and seven prevention trials identified met the inclusion criteria. All trials included compared one of the drugs against placebo or standard care. Treatment of children, otherwise healthy individuals, and high risk populations with zanamivir reduced the median duration of symptoms in days respectively by 1.0 (95% confidence interval 0.5 to 1.5), 0.8 (0.3 to 1.3), and 0.9 (-0.1 to 1.9) for the intention to treat population. The corresponding results, in days, for oseltamivir were 0.9 (0.3 to 1.5), 0.9 (0.3 to 1.4), and 0.4 (-0.7 to 1.4). The effect of giving zanamivir and oseltamivir prophylactically resulted in a relative reduction of 70-90% in the odds of developing flu, depending on the strategy adopted and the population studied.

Conclusions: Evidence from randomised controlled trials consistently supports the view that both oseltamivir and zanamivir are clinically effective for treating and preventing flu. However, evidence is limited for the treatment of certain populations and for all prevention strategies.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Flow diagram of systematic review
Fig 2
Fig 2
Forest plot of difference in time to alleviation of symptoms between zanamivir and placebo arms, by the three intention to treat populations
Fig 3
Fig 3
Forest plot of difference in time to alleviation of symptoms between zanamivir and placebo arms, by the three flu positive populations
Fig 4
Fig 4
Forest plot of difference in time to alleviation of symptoms between oseltamivir and placebo arms, by the three intention to treat populations
Fig 5
Fig 5
Forest plot of difference in time to alleviation of symptoms between oseltamivir and placebo arms, by the three flu positive populations
See this image and copyright information in PMC

Comment in

References

    1. Nicholson KG, Webster RG, Hay AJ. Textbook of influenza. Oxford: Blackwell Science, 1998.
    1. Cochran K, Maasasab H, Tsunoda A, Berlin BS. Studies on the antiviral activity of amantadine hydrochloride. Ann N Y Acad Sci 1965;130: 432-9. - PubMed
    1. Tsunoda A, Maasab HF, Cochran KW, Eveland WC. Antiviral activity of alpha-methyl-1-admantanemethylamine hydrochloride. Antimicrobial Agents Chemother 1965;5: 553-60. - PubMed
    1. Hayden F, Hoffman H, Spyker D. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrobial Agents Chemother 1983;23: 458-64. - PMC - PubMed
    1. Millet VM, Dreisbach M, Bryson YJ. Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine. Antimicrobial Agents Chemother 1982;21: 1-4. - PMC - PubMed

Publication types

MeSH terms